In a filing, Kura Oncology Inc revealed its Chief Legal Officer Bair Teresa Brophy unloaded Company’s shares for reported $9292.0 on May 19 ’25. In the deal valued at $5.96 per share,1,559 shares were sold. As a result of this transaction, Bair Teresa Brophy now holds 107,948 shares worth roughly $0.7 million.
Then, FORD KATHLEEN sold 1,558 shares, generating $9,777 in total proceeds. Upon selling the shares at $6.28, the Chief Operating Officer now owns 21,367 shares.
Before that, FORD KATHLEEN bought 1,558 shares. Kura Oncology Inc shares valued at $9,286 were divested by the Officer at a price of $5.96 per share.
BTIG Research downgraded its Kura Oncology Inc [KURA] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Stifel also remained covering KURA and has decreased its forecast on October 14, 2024 with a “Hold” recommendation from previously “Buy” rating. Mizuho started covering the stock on December 22, 2023. It rated KURA as “a Buy”.
Price Performance Review of KURA
On Monday, Kura Oncology Inc [NASDAQ:KURA] saw its stock jump 0.78% to $6.49. Over the last five days, the stock has lost -3.57%. Kura Oncology Inc shares have fallen nearly -25.49% since the year began. Nevertheless, the stocks have fallen -70.06% over the past one year. While a 52-week high of $23.48 was reached on 02/05/25, a 52-week low of $5.41 was recorded on 04/07/25.
Levels Of Support And Resistance For KURA Stock
The 24-hour chart illustrates a support level at 6.34, which if violated will result in even more drops to 6.20. On the upside, there is a resistance level at 6.60. A further resistance level may holdings at 6.72.
The most recent change occurred on August 11, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $31 price target.
